Helsinn Healthcare SA
- Country
- 🇨🇭Switzerland
- Ownership
- Holding
- Established
- 1976-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.helsinn.com
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
- Conditions
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Helsinn Healthcare SA
- Registration Number
- NCT05222165
- Locations
- 🇨🇦
McMaster Children's Hospital (MCH), Hamilton, Ontario, Canada
🇨🇦University of Alberta - Stollery Children's Hospital (SCH), Edmonton, Alberta, Canada
🇺🇸Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
Oral Akynzeo® Vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)
- Conditions
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 414
- Registration Number
- NCT04817189
- Locations
- 🇨🇳
Shanghai Ninth People´s Hospital, Shanghai, China
🇩🇪Klinikum Ernst von Bergmann gemeinnützige GmbH, Potsdam, Germany
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
- Conditions
- Interventions
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 202
- Registration Number
- NCT04683250
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇯🇵National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇺🇸Stanford Cancer Center, Stanford, California, United States
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 318
- Registration Number
- NCT03743051
- Locations
- 🇺🇸
Englewood Health, Englewood, New Jersey, United States
🇮🇹Versilia Hospital, Lido Di Camaiore, Italia, Italy
🇷🇴S.C. Onco Clinic Consult SA, Craiova, Dolj, Romania
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 318
- Registration Number
- NCT03743064
- Locations
- 🇺🇸
The University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States
🇺🇸Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
🇺🇸New Jersey Hematology Oncology Associates Inc, Brick, New Jersey, United States
Effects of Aqualief® in Patients With Xerostomia as Consequence of Radiotherapy for Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 100
- Registration Number
- NCT03601962
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The Body
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 6
- Registration Number
- NCT03495934
- Locations
- 🇬🇧
Quotient Science, Ruddington, United Kingdom
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 404
- Registration Number
- NCT03403712
- Locations
- 🇺🇸
CBCC Global Research, INC at Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸Mercy Medical Center, Medical Oncology and Hematology, Baltimore, Maryland, United States
Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®
- Conditions
- Interventions
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 80
- Registration Number
- NCT03255980
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 67
- Registration Number
- NCT03204279
- Locations
- 🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States
🇷🇺Chelyabinsk Regional Children's Clinical Hospital, Chelyabinsk, Russian Federation
🇺🇦National Institute of Cancer, Research Department of Pediatric Oncology, Kyiv, Ukraine